<DOC>
	<DOCNO>NCT02933554</DOCNO>
	<brief_summary>Obesity epidemic US . With progression obesity , Nonalcoholic steatohepatitis ( NASH ) grow public health issue . Presently cure NASH.Prevention progression fibrosis NASH crucial , high risk cirrhosis may need liver transplant . Recent study show block blood vessel particular portion stomach ( bariatric leave gastric artery embolization ) temporarily decrease level appetite induce hormone ghrelin , result weight loss.The purpose study determine Left gastric artery embolization ( LGAE ) patient obesity NASH lead clinically significant weight loss improvement NASH .</brief_summary>
	<brief_title>Bariatric Embolization Arteries Treatment Nonalcoholic Steatohepatitis</brief_title>
	<detailed_description>Obesity : In adult , obesity define BMI great 30 kg/m2 . It estimate , year 2030 , 38 % world 's adult population overweight another 20 % obese.An expert panel convene NIH state first time history , steadily improve worldwide life expectancy could level even decline , result increase obesity . NAFLD NASH : The Problem : Obesity chronic disease strongly associate number disease increase mortality morbidity . Metabolic syndrome ( obesity , diabetes mellitus , hyperlipidemia ) establish risk factor primary nonalcoholic fatty liver disease ( NAFLD ) .In US , recent estimate suggest NAFLD affect 30 % general population , 90 % morbidly obese . NAFLD progress nonalcoholic steatohepatitis ( NASH ) 25 % . Of patient NASH progression fibrosis see 26-37 % progress cirrhosis 9-25 % . NASH cirrhosis result liver failure , portal hypertension , hepatocellular carcinoma ( HCC ) . Current option management NASH : The goal manage NASH eliminate risk factor prevent fibrosis treat metabolic syndrome , primarily obesity [ 10 ] . Although dietary modification exercise achieve weight loss , difficult sustain . Very effective medical therapy available , associated adverse effect . Although weight loss bariatric surgery demonstrate histological improvement NASH , recent Cochrane review conclude insufficient data determine bariatric surgery effective treatment . Also high mortality rate see post-bariatric surgery . Thus safe effective minimally invasive option need . Based currently available data , Left gastric artery embolization ( LGAE ) appear effective induce weight loss 10.5 % 3-6 month , high safety profile . In patient NAFLD , 3-5 % weight loss think improve steatosis , 7- 10 % may need improve necroinflammation . Thus , LGAE potential reverse histology NASH prevent progression cirrhosis , HCC sequale .</detailed_description>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Male Female , age 22 year old . Willing , able mentally competent provide write informed consent willing comply study procedure available duration study BMI &gt; 35 kg/m2 Adequate hematological , hepatic renal function follow : Hematological : Platelets &gt; 50 x 109/L , INR &lt; 1.5 Hepatic : Total bilirubin &lt; 3 mg/dL Renal : Estimated GFR &gt; 60ml/min.1.73m2 Elevated alanine aspartate aminotransferase value ( ALT &gt; 41 AST &gt; 34 U/L ) . Liver biopsy show evidence NASH past 12 month . No evidence another form liver disease . Patients diagnose NASH evidence fail method weight loss diet , exercise behavior modification . Pregnancy Active substance abuse Significant psychiatric problem , severe enough cause suffer poor ability function life . Center Epidemiological Studies Depression ( CESD ) score &lt; 16 . Significant alcohol consumption ( &gt; 20 g/day woman , &gt; 30 g/day men ) Weight &gt; 400 lb , BMI &gt; 50 kg/m2 . Contraindications obtain liver biopsy Subjects preexist abdominal pain exclude ( potential confusion pain related procedure ) . Subjects intolerant PPIs Subjects require anticoagulant medication exclude . Subjects take aspirin/ NSAIDs medication unable withdrawn aspirin NSAIDs least 3 day prior LGAE procedure 30 day follow LGAE procedure ( potential risk gastric bleed following procedure ) . Presence systemic illness medical condition relevant survival . ( Note HCC pre liver transplant cohort , presence HCC consider exclusion criterion ) Metastatic cancer Evidence decompensated liver disease ( uncontrolled ascites , uncontrolled spontaneous encephalopathy ) Prior surgical weight loss procedure include gastroplasty , jejunoileal , jejunocolic bypass , total parenteral nutrition within past 6 month ; Prior history gastric pancreatic , hepatic , and/or splenic surgery Prior embolization stomach , spleen liver . If review available prior imaging study ( i.e CT , MRI , US ) show potential anatomical variation , presence severe atheromatous disease , large arteriovenous shunt blood . Abnormal Endoscopy large slide hiatal hernia paraesophageal hernia , active peptic ulcer disease , active H. pylorus infection History abnormal Nuclear Gastric Motility examinationdefined delayed empty gastric content &gt; 90 % , 60 % 10 % 1 hour , 2 hour , 4 hour respectively . ASA Class 4 5 Child Pugh classification C Known aortic disease , dissection aneurysm ; peripheral arterial disease cardiovascular disease . Type 2 diabetes antidiabetic medication know cause hypoglycemia . e.g . sulphonylureas , meglitinidine Patients know cause increase liver enzyme level viral hepatitis ( B C ) , autoimmune/chronic immune hepatitis , primary biliary cholangitis , metabolic genetic hemochromatosis , Wilson 's disease , alpha1 antitrypsin deficiency Patient take hepatotoxic drug . List drug cause steatohepatitis include limit : amiodarone , chemotherapy ( 5fluorouracil , tamoxifen , irinotecan , cisplatin , asparaginase ) , glucocorticoid , methotrexate , sulfonamide , antithyroid drug , phenytoin , tetracycline , isoniazid , salicylate , valproic acid . Contraindications obtain liver biopsy ( NASH cohort ) Patients take trial medication NASH .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>bariatric surgery</keyword>
	<keyword>minimally invasive</keyword>
	<keyword>Embolization</keyword>
	<keyword>NASH</keyword>
	<keyword>ghrelin</keyword>
	<keyword>gastric artery embolization</keyword>
</DOC>